Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Ilunocitinib (Zenrelia): A Clinical Guide to the Once-Daily JAK Inhibitor for Canine Atopic Dermatitis
Ilunocitinib (Zenrelia, Elanco) is a once-daily oral JAK inhibitor for canine allergic and atopic dermatitis. This hub covers mechanism, dosing, the head-to-head data versus oclacitinib, the boxed vaccination warning, and where it fits alongside Apoquel, Cytopoint, and ciclosporin.
Read →Sarolaner for Canine Generalized Demodicosis: Efficacy, Class Pharmacology, and Safety
Oral sarolaner-based isoxazolines clear Demodex canis in generalized demodicosis: a masked field study reached 100% mite reduction by Day 90.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evergreen review of pivotal RCTs, 12-month durability, ciclosporin comparison, COLT combination therapy, and the 2024-2025 JAK-inhibitor landscape.
Read →Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
Two controlled studies confirm 98–100% mite-free rates with a single fluralaner administration for canine generalized demodicosis, outperforming imidacloprid/moxidectin — with 2026 data extending single-dose cure to sarcoptic mange and reviews refining the isoxazoline MDR1 neurologic-safety signal.
Read →Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety
Atopica for Cats produced a 65.1% lesion score reduction vs 9.2% in controls in a 181-cat field study. FDA-indicated for miliary dermatitis, eosinophilic plaques, excoriations, and self-induced alopecia.
Read →Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use
Evidence-based guide to cyclosporine (Atopica/Cyclavance) for canine atopic dermatitis: RCT efficacy vs placebo and methylprednisolone, the ~4-week onset and prednisolone bridging strategy, long-term safety, vaccination planning, CYP3A4 interactions, and feline PK contrast.
Read →Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
Oclacitinib (Apoquel) for canine atopic dermatitis: 24-hour onset RCT data, head-to-head vs prednisolone, ciclosporin, and ilunocitinib, 10-year safety and neoplasia evidence, JAK1 mechanism, combination protocols, and monitoring.
Read →